By Nigel Somerville | Tuesday 20 November 2018
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Privately held Immunocore, which forms part of the Neil Woodford estate, has announced some good news: it has signed a deal with Genetech, part of Roche Group, for the development of Immunocore’s IMC-C103C drug aimed at targeting the MAGE-A4 protein (Melanoma-Associated Antigen A4). The really good news is that Genetech is to hand over $100 million in upfront and near-term milestone payments, and upon establishing proof-of-concept there is an option to co-develop the treatment or license the treatment to Genetech for royalty and milestone payments. Needless to say, Woodford Patient Capital Trust (WPCT) rushed out a statement too...
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.
Filed under:
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Time left: 08:09:49